Skip to main content

PharmTeam’s Activity

Wed Feb 26

NL

Article

PharmTeam published an article 11:38 AM

3 Things to Watch When Isis Pharmaceuticals Reports 2013 Earnings

This RNA therapeutics powerhouse should provide some insightful updates as it enters a critical point in its growth.

Thu Feb 13

NL

Article

PharmTeam published an article 11:59 PM

The Amazon.com and Facebook of Health Care

An investment in athenahealth is an investment in CEO Jonathan Bush's vision for an interconnected health care internet.

Wed Feb 12

NL

Article

PharmTeam published an article 8:30 AM

3 Trends That Could Define Drug Discovery in 2014

These clear trends could help investors identify winning companies in 2014 and beyond.

Mon Feb 3

NL

Article

PharmTeam published an article 6:30 PM

Time for a Turnaround at Teva Pharmaceuticals Industries Ltd?

Are Teva's management and patent woes finally a thing of the past?

NL

Article

PharmTeam published an article 6:30 PM

Timing is Everything for this Health Care IT Provider

Veeva Systems has an innovative platform to meet the growing demand for cost-cutting in the health care sector.

Wed Jan 22

NL

Article

PharmTeam published an article 6:30 PM

2014: The Year of Personalized Medicine

After a 2013 of massive improvements to cancer therapy, will 2014 be the year doctors can quickly determine which patients will benefit from which therapies?

NL

Article

PharmTeam published an article 7:30 AM

What to Watch When Bristol-Myers Squibb Reports End of Year Earnings

Can Bristol-Myers put its capital to good use and push its hepatitis and oncology segments to success?

Mon Jan 6

NL

Article

PharmTeam published an article 1:06 PM

A Busy Week for Cardiac Health at the FDA

Chelsea, Merck, and Johnson & Johnson state their cases for approval in front of an FDA panel. Here's everything you need to know to stay ahead of the game.

Fri Jan 3

NL

Article

PharmTeam published an article 11:09 AM

Cancer Immunotherapy: The Breakthrough of 2013

With Roche, Merck, and Bristol-Myers Squibb posting impressive clinical trial results, immunotherapy represents a major breakthrough in treating cancer.

Mon Dec 30

NL

Article

PharmTeam published an article 3:30 PM

3 Health Care Investments Immune From FDA Scrutiny

Veeva Systems, Express Scripts, and Repligen operate in the health care space but don't rely on the good graces of FDA regulators.

Thu Dec 5

NL

Article

PharmTeam published an article 11:51 AM

3 Biotech Flops of 2013

2013 was a great year for the biotech industry as a whole, but Achillion, Prosensa, and Amarin didn't share the joy.

Mon Dec 2

NL

Article

PharmTeam published an article 4:34 PM

Can Heart Drugs Disrupt an Emerging Breast Cancer Market?

A surprising finding published last week could open a door for statins to prevent breast cancer.

Tue Nov 19

NL

Article

PharmTeam published an article 2:10 PM

Clarifying Breakthrough Designation at the FDA

The new designation will help drugs get to patients with serious diseases much more quickly, and it can spur excitement surrounding a company's stock.

Sun Nov 17

NL

Article

PharmTeam published an article 9:12 AM

A Shifting Paradigm in Heart Disease Could Affect These Drugmakers

Amgen, Regeneron, and Sanofi are among the companies impacted by a change to the cardiologist's mindset.

Fri Nov 8

NL

Article

PharmTeam published an article 10:53 AM

A Busy Day of Layoffs in Pharma

The big pharma cost cutting continues as Novartis, Bristol-Myers Squibb, and Ariad Pharmaceuticals announce staff cuts.

Tue Nov 5

NL

Article

PharmTeam published an article 6:13 PM

3 Things Investors Should Know From Isis' Earnings Report

Isis Pharmaceuticals has had an eventful year, and this quarter was no different.

Sun Nov 3

NL

Article

PharmTeam published an article 10:44 PM

A Health Care Portfolio for the Ages: The Platform Play

This week we'll add a high growth prospect to our market-beating health care virtual portfolio.

Fri Oct 25

NL

Article

PharmTeam published an article 2:09 PM

A Health Care Portfolio for the Ages: The Stalwarts

In this week's edition, we'll add two dividend-paying stalwarts, Johnson & Johnson and Abbott Labs, to our HealthyMoney CAPS virtual portfolio.

Wed Oct 23

NL

Article

PharmTeam published an article 4:28 PM

3 Takeaways From Amgen's Earnings Report

Investors have a lot to chew on after Amgen's third quarter earnings. This should help them digest the results.

Thu Oct 17

NL

Article

PharmTeam published an article 1:44 PM

Is Amarin's FDA Panel Important for Other Cardiovascular Drugmakers?

Other companies with drugs that lower triglycerides were watching Amarin's FDA panel closely.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 69.63
Player Rank 20616 out of 67886
Score 2736.76
Score Change Today -45.63
Accuracy 44.74%
Active Picks 49
Total Picks 76
Best Pick AMZN (+637.42)
Worst Pick TVIA (-226.61)
Average Score per Pick 36.01
Charms Earned 10
Highest Rated Favorite No Favorites Selected
Go to PharmTeam’s CAPS page

Boards Stats & Trivia

Board Posts 40
Recs Received 51
People who have rec'd these posts 30
Recs to Posts Ratio (last 30 days) N/A
Threads Started 14
Threads Started Percentage 35.00 %
Most Frequent Board Premium Boards
Very First Post A $: Amazon.com post. (12/1/2013)
Percentage of Posts Rec'd 57.50 %
Show PharmTeam’s 10 Latest Posts
The Motley Fool respects your privacy and strive to be transparent about our data collection practices. We use your information to customize the site for you, to contact you about your membership, provide you with promotional information, and in aggregate to help us better understand how the service is used. For more details, please review our Privacy Policy.